Patients with epilepsy who respond to eslicarbazepine acetate (ESL), have a seizure frequency reduction (SFR) of ≥75%, and are at the lower SFR threshold of ≥50% have higher health-related quality of life (QoL) compared with nonresponders to ESL, according to study results reported in Epilepsy & Behavior.
Researchers from the United States pooled patient data from 2 multicenter, randomized, double-blind, historical control phase 3 trials, both of which investigated the conversion to ESL monotherapy in adults with partial-onset seizures that were not adequately controlled. In the pooled cohort, a total of 252 patients were included in the efficacy population (intent-to-treat] who entered the 8-week medication taper/conversion period), and 211 patients were included in the completer population (efficacy patients who completed the ESL-only period). Individuals who met the SFR ≥50% threshold (responders) and patients with SFR <50% (nonresponders) were compared in terms of the association between health-related QoL and response to ESL by week 18 Quality of Life in Epilepsy-31 scores. An SFR ≥75% threshold was used in an analysis performed in both the efficacy and completer population.
Treatment responders with ≥50% SFR in the efficacy population had higher week 18 Quality of Life in Epilepsy -31 total score least squares mean (LSM) compared with nonresponders (LSM difference 3.0; 95% CI, 0.2-5.8; P =.037). Responders with ≥75% SFR also had higher scores (LSM difference 7.0; 95% CI, 3.6-10.3; P <.001). Responders with ≥50% SFR in the completer population had higher overall QoL (LSM difference 5.1; 95% CI, 1.5-8.6; P =.006) and social functioning (LSM difference 5.4; 95% CI, 0.1-10.7; P =.046) compared with nonresponders. All 7 LSM domains were also higher among responders with ≥75% SFR (all P <.05).
Limitations of the study included its retrospective nature and the narrow analysis population included in the final cohort.
The researchers concluded by noting that future research is needed “to identify predictors for achievement of clinically meaningful change.”
Cramer JA, Rajagopalan K, Anastassopoulos KP, Blum D, Covance. Health-related quality of life in patients treated with eslicarbazepine acetate monotherapy: pooled analysis from two registered clinical trials. Epilepsy Behav. 2019;92:31-35.